Employees' Retirement System of the City of Baton v. Macrogenics, Inc., 61 F.4th 369

Background

MacroGenics, a clinical‑stage biopharmaceutical company, ran the Phase 3 SOPHIA trial of margetuximab vs. trastuzumab in HER2+ metastatic breast cancer with co‑primary endpoints: progression‑free survival (PFS) and overall survival (OS).
On Feb. 6, 2019 MacroGenics announced topline PFS success; press release and calls noted OS follow‑up was ongoing and that OS data were immature.
On Feb. 13 MacroGenics completed a secondary stock offering whose prospectus incorporated the Feb. 6 release and included detailed risk disclosures cautioning that topline/interim data may change and that one endpoint’s success does not guarantee another.
On May 15 MacroGenics disclosed interim OS results from the Oct. 10, 2018 cut‑off (158 OS events, ~41% of required events) and described a preliminary positive trend favoring margetuximab; stock rose briefly.
On June 4 at ASCO MacroGenics presented Kaplan‑Meier curves of the interim OS data showing curves that crossed and later diverged; analysts reacted negatively and the stock fell ~22% over two days.
Plaintiffs brought securities claims under §10(b)/Rule 10b‑5, §20(a), §§11/12/15 of the Securities Act, alleging Defendants made misleading statements/omissions and failed to disclose the Kaplan‑Meier graph; the district court dismissed and the Fourth Circuit affirmed.

Issues

Issue	Plaintiff's Argument	Defendant's Argument	Held
Whether statements about PFS/overall SOPHIA progress put interim OS data “in play” so as to create a duty to disclose the Kaplan‑Meier curves	Feb. and other statements (incl. optimistic commentary) put OS squarely in play and thus required disclosure of the Kaplan‑Meier graph	Statements focused on PFS and repeatedly cautioned OS data were ongoing and immature; no duty to disclose interim graph	No duty to disclose; reasonable investors would not be misled into thinking OS was definitive from the PFS announcement
Whether positive statements re: interim OS were materially false or misleading (misrepresentation/omission)	Positive characterizations were misleading because the Kaplan‑Meier curves objectively undercut the optimism and were withheld	Positive statements were opinions/puffery or accurate interpretations of the interim data and were hedged with cautionary language	Statements were not actionable misrepresentations; plaintiffs’ contrary interpretation was a nonactionable difference of opinion
Whether statements are protected as opinion/puffery or by PSLRA Safe Harbor (forward‑looking)	Plaintiffs: optimism was presented as fact and induced investors; Safe Harbor inapplicable	Defendants: many statements were opinions/puffery, hedged, and forward‑looking ("anticipate the trend to continue") with meaningful cautionary language	Many statements were inactionable puffery/opinion and forward‑looking statements fell within Safe Harbor or lacked pleaded actual knowledge of falsity
Whether Offering Documents (Items 303/105) and Prospectus omitted material risks under the Securities Act (§§11,12)	Risk warnings were boilerplate and failed to disclose the specific adverse OS trend known prior to the offering	Offering Documents explicitly warned topline/interim data may change, that PFS success does not guarantee OS, and specifically cautioned OS follow‑up was ongoing	Risk disclosures were sufficiently specific and tailored; §§11/12 and Item 303/105 claims fail

Key Cases Cited

Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (establishes standards for pleading scienter under PSLRA)
Matrixx Initiatives, Inc. v. Siracusano, 563 U.S. 27 (duty to disclose nonpublic facts when necessary to make public statements not misleading)
Omnicare, Inc. v. Laborers Dist. Council Constr. Indus. Pension Fund, 575 U.S. 175 (opinion statements actionable only if not honestly held or lack reasonable basis)
Stoneridge Inv. Partners, LLC v. Scientific–Atlanta, Inc., 552 U.S. 148 (elements required for §10(b)/Rule 10b‑5 claims)
Zak v. Chelsea Therapeutics Int’l, Ltd., 780 F.3d 597 (duty to disclose where public statements conflict with known nonpublic information)
Singer v. Reali, 883 F.3d 425 (when generic warnings are insufficient to cure materially misleading disclosures)
Cozzarelli v. Inspire Pharm., Inc., 549 F.3d 618 (context on biotech disclosures and pleading/amendment principles)
Longman v. Food Lion, Inc., 197 F.3d 675 (puffery doctrine)
Greenhouse v. MCG Capital Corp., 392 F.3d 650 (materiality standard)
Lerner v. Nw. Biotherapeutics, 273 F. Supp. 3d 573 (D. Md.) (interpretation of clinical trial data as opinion)